• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

cell - Articles and news items

Celyad completes safety follow-up in the second dose level of patients in its NKR-2 trial

Industry news / 25 February 2016 / Victoria White

The Phase I trial is designed to assess the safety and feasibility of NKR-2, in two different haematological indications…


Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +